120 results about "Brains tissue" patented technology

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The invention relates to a fetal brain tissue segmentation method based on prior information guidance, and the method comprises the following steps: obtaining a public data set, and selecting a part of data in the public data set as a training set; preprocessing the training set to obtain a grey-white matter volume ratio, an edge feature map and a gestational week feature map; constructing a prior segmentation model GA-Swin, and designing a loss function LTotal to train the model; and finally obtaining a trained fetal brain segmentation model. According to the method, on the basis of following the development law, each tissue of the fetal brain can be precisely segmented, and collaborative optimization of precision interpretability and biological rationality in medical image analysis is achieved.

The invention provides a rigidity-flexibility variable multifunctional optical genetic implantable probe and a preparation method thereof. The probe comprises a thin film electrode layer and a rigidity-flexibility variable shape memory layer arranged at the bottom of the thin film electrode layer. The micro LED is integrated in the flexible nerve probe through contact type laser transfer printing to serve as a light stimulation light source, the preparation success rate is remarkably increased, heat radiated outwards during light stimulation is reduced, and damage to brain tissue of the brain caused by high-Young-modulus optical fibers is avoided; meanwhile, a rigid-flexible variable shape memory layer is also integrated, so that the Young modulus of the probe is high when the in-vitro temperature is relatively low, fixed-point implantation can be directly carried out without an auxiliary tool, the Young modulus of the probe is reduced along with the rise of the body temperature after the probe is implanted into the body, and the probe finally adapts to the mechanical tissue strength of the brain; therefore, the implantation efficiency and the mechanical adaptability of the probe to brain tissues are improved, and micron-scale accurate implantation of the probe, neuron-scale positioning of electrical stimulation and light stimulation points and long-term stable recording of electrophysiological signals are realized.

The invention belongs to the technical field of nutritional compositions, and particularly relates to a composition, a preparation method thereof and application of the composition in protecting brain health. The composition provided by the invention is prepared from docosahexaenoic acid, 3-sialic acid lactose and phosphatidylserine. The composition is clear in sleep improvement effect, can effectively solve the problem of sleep maintenance caused by sleep deprivation, has the effects of protecting neural functions, improving memory and relieving anxiety from multiple dimensions, and can repair brain tissue damage and protect brain health. Based on the composition, products for assisting in improving memory, preventing and treating insomnia and anxiety, regulating neurodevelopmental disorders, protecting brain health and improving concentration can be developed, the health requirements of different people are comprehensively met, and the application value is high.

This invention belongs to the field of pharmaceutical technology, specifically relating to a quinazoline-azaindole compound, its preparation method, and its application in treating Alzheimer's disease. The quinazoline-azaindole compound of this invention regulates NF-κB by inhibiting DYRK1A. k B. A series of signaling pathways, including PI3k-Akt, achieve anti-neuroinflammatory effects; quinazoline-azaindole compounds can reduce the expression of inflammatory factor-related genes in an LPS-induced BV2 microglial inflammation model, thereby reducing the levels of inflammatory factors in the hippocampus and cortex, alleviating neuronal pathological damage caused by neuroinflammation, and improving cognitive impairment caused by neuroinflammation; in summary, quinazoline compounds inhibit DYRK1A and downregulate NF-κB signaling pathways. k It can reduce the expression and release of inflammatory factors, improve brain tissue pathology, and alleviate cognitive impairment through signaling pathways such as B, and has significant clinical application value.

The present application belongs to the field of functional substance research, and particularly relates to a nutritional composition for promoting brain development and use thereof. The nutritional composition provided by the present application comprises essential active ingredients shown in (i) and (ii) as follows: (i) lysophosphatidylethanolamine; (ii) 3'-SL; wherein the essential active ingredient shown in (i) at least comprises lysophosphatidylethanolamine with a fatty acid chain with a length of 14-22 carbon atoms connected at the sn-1 position, and in the nutritional composition, the mass ratio of the essential active ingredient shown in (i) to the essential active ingredient shown in (ii) is 1:(1-450). The combination of lysophosphatidylethanolamine and breast milk oligosaccharide 3'-SL can effectively promote the overall development of the body, especially the brain development, and improve the relative gene expression amount of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, thereby effectively assisting the improvement of cognitive ability.

The invention belongs to the technical field of molecular biology, and relates to an application of transferrin (TF) as an internal reference protein in preparation of a reagent for detecting exosome proteins of neurodegenerative diseases. The TF can maintain a stable expression level in nerve cells, brain tissues, blood plasma and serum-derived exosomes of a subject suffering from neurodegenerative diseases, including Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease, and also including neurodegenerative diseases such as Alzheimer's disease, mild cognitive impairment, amyotrophic lateral sclerosis, Parkinson's disease or Huntington's disease. The TF expression variation coefficient is obviously lower than that of a common exosome marker, and the expression level of TF has stronger correlation with the total protein amount of the exosome and is not influenced by external factors such as cell inflammation stress. The TF as the internal reference protein has more excellent performance, can help to more accurately reflect the total loading amount of the sample, and provides a more stable and reliable standardized tool for the field of exosome research.

A system may comprise hardware and software configured to perform computing functions that mimic at least one computing function of a human brain, wherein the hardware and software comprises: analog circuitry configured to perform signal processing of neural signals obtained from living brain tissue using at least one sensor, a computer system comprising a processor, memory accessible by the processor, and computer program instructions stored in the memory and executable by the processor digital circuitry and software configured to process the obtained neural signals to generate a representation of a brain function from the obtained neural signals, and to generate parameters for use by analog and digital circuitry to perform computing functions that mimic at least one computing function of a human brain, and the analog and digital circuitry configured to use the generated parameters to perform computing functions that mimic at least one computing function of a human brain.

The invention relates to the technical field of traditional Chinese medicines, relates to new application of a traditional Chinese medicine composition, and in particular relates to application of the traditional Chinese medicine composition in preparation of a medicine for preventing and / or treating migraine. The traditional Chinese medicine composition is prepared from cassia twig, white peony root, honey-fried licorice root, ginger, jujube, ginseng, Chinese angelica, salted morinda officinalis and dwarf lilyturf tuber. The traditional Chinese medicine composition provided by the invention can obviously reduce serum NO and trigeminal nervous tissue SP content of migraine rats, increase trigeminal nervous tissue DA content, obviously improve head and face pain threshold and brain tissue DA content of the migraine rats and reduce brain tissue PGE2 content, and has a good treatment effect on migraine.

The present disclosure provides anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that preferentially bind to soluble amyloid [beta] fibrils / oligomers and trigger ADPC in microglial cells; anti-amyloid [beta] (A [beta]) antibodies and antibody fragments that reduce soluble amyloid [beta] fibril / oligomer levels and insoluble amyloid [beta] plaques in brain tissue; and the use of anti-A [beta] fibril / oligomer antibodies and antibody fragments in the treatment, prevention, diagnosis, screening and monitoring of conditions associated with A [beta] protein aggregation, in particular Alzheimer's Disease (AD).

The invention provides a cleaning and preserving fluid for fetal brain tissues and a preserving method thereof, and belongs to the technical field of tissue preservation. The cleaning and preserving fluid comprises trehalose, nerve growth factors, a GlutaMAX supplement, Y27632, S-nitrosoglutathione, tert-butylhydroquinone, a Versene solution and polyvinylpyrrolidone, compared with a traditional tissue preserving fluid, the cleaning and preserving fluid not only can improve the purity of neural stem cells, but also can maintain the activity and the yield of the neural stem cells in fetal brain tissue, and the cleaning and preserving fluid has the advantages that the cleaning and preserving fluid is simple in structure and convenient to use. The structural integrity of the cells is guaranteed, a high-quality sample is provided for subsequent research on proliferation, differentiation and the like of the neural stem cells, and the method has a wide application prospect.

The present invention relates to recombinant vectors comprising AIMP2 splice variants and miR-142 target nucleic acids and various applications thereof. The AIMP2 variants can be specifically expressed in neuronal cells and brain tissue, and thus can be beneficially applied in related industries.

The present invention discloses a pharmaceutical composition comprising more than 26 substances, obtained by mixing ethanol extracts of costus root, agarwood, jujube, terminalia chebula, nutmeg, kapok, and frankincense with travertine. The composition can improve myocardial ischemia in subjects; increase the ejection fraction of subjects with myocardial infarction; increase the fractional shortening of the heart; reduce the left ventricular end-diastolic diameter in subjects with myocardial infarction; reduce the left ventricular end-systolic diameter in subjects with myocardial infarction; shorten the sleep latency in subjects with insomnia; prolong the sleep duration in subjects; and upregulate the expression of GAD67 protein in the brain tissue of subjects.

This application relates to the field of medicinal chemistry, specifically disclosing a piperidine derivative, a pharmaceutical composition, its uses, and a method for preparation. The piperidine derivative has the structure of general formula (I). This piperidine derivative can significantly improve the learning and memory abilities of Aβ-induced Alzheimer's disease model rats and effectively reduce acetylcholinesterase activity in brain tissue, providing a potential candidate for the development of novel Alzheimer's disease treatments.

The present invention relates to a female neuroendoscope sleeve assembly for deep ventricles, comprising a primary sleeve, a primary sleeve core, a secondary sleeve, and a secondary sleeve core. The primary sleeve and the secondary sleeve can be nested with each other to construct a primary channel, and the secondary sleeve and the secondary sleeve core can be nested with each other and inserted into the primary sleeve to construct a secondary channel. Through the orderly coordination of the various components in the assembly, the replacement between a primary sleeve with a larger diameter and a shorter tube length for shallow brain tissue surgery and a secondary sleeve with a smaller diameter and a longer tube length for deep brain tissue surgery can be completed through coaxial exchange technology. The use of a thinner, more mobile, less brain-damaging, and more accurately positioned secondary sub-tube to enter deep tissue or ventricles is very beneficial to the protection of deep brain functional nuclei and numerous thin-walled arteries and veins in the ventricular wall, reducing surgical side effects, lowering surgical risks, and improving the patient's neurological function prognosis.

The invention belongs to the technical field of biology, and particularly relates to a construction method of a respiratory syncytial virus infected mouse model. Disodium clodronate liposome with the concentration of 4ng / mL is injected into the lateral ventricle of the mouse through stereotactic positioning of the brain. 48h after injection, mouse brain tissues are taken to detect the activation state of microglial cells through immunofluorescence and WB, after it is confirmed that the microglial cells are inhibited, RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments are carried out on the mouse, and after the 5th day after virus infection, the mouse is infected by the RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments. Likewise, mouse brain tissue is taken for virus load detection, and neuropathological changes of the mouse brain tissue are observed through HE staining, immunofluorescence and TUNEL staining, so that the method can be used for constructing a research model of RSV-related nervous system diseases.

The present invention provides a fetal brain tissue segmentation method, device, medium and terminal based on a cycle consistency network. By acquiring target fetal brain image data, inputting the target fetal brain image into a pre-trained cycle consistency network, and outputting a segmentation result of the target fetal brain image corresponding to the gestational week; The present invention adopts a learning framework combining cycle consistency and adversarial learning, and realizes the accurate capture of fine-grained domain-invariant brain structures in thick clinical and thin reconstruction cases of fetal brain MR images.

The invention discloses application of a reagent for detecting an SLC17A7 autoantibody in diagnosis of nervous system diseases. By comparing different fluorescence modes of autoimmune antibodies related to IgG of healthy people in mouse brain tissue slices of patients with nervous system diseases, it is found that fluorescence signals only exist in the patients with nervous system diseases and do not exist in the healthy people, and it is prompted that the patients possibly have the autoimmune antibodies. According to the invention, IgG specific protein related to nervous system diseases is sought through a co-immunoprecipitation technology, a specific SLC17A7 autoantibody is found through cell immunofluorescence (CBA) detection, verification is carried out in cerebrospinal fluid, and finally it is determined that the SLC17A7 autoantibody can be used as a specific marker for diagnosis of nervous system autoimmune diseases. The SLC17A7 is taken as a detection antigen, detection of the expression of the SLC17A7 autoantibody can be applied to a kit for detecting the SLC17A7 autoantibody, the kit can be applied to detection of nervous system diseases, markers for identifying the nervous system diseases are enriched, and the detection accuracy of nervous system related diseases is improved.

The application provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine preparation is composed of nacre, antelope horn powder, dragon's blood, Herba Schizonepetae, Prunella vulgaris, Stink-bug, Smilax riparia, bamboo juice, dried tangerine or orange peel, clubmoss, radix puerariae, Zizania aquatica and leaf of Chinese pear. The preparation has a significant therapeutic effect on cerebral hemorrhage, can obviously improve the neurological deficit of cerebral hemorrhage rats, reduce the water content of brain tissue to alleviate brain edema, simultaneously alleviate the inflammatory response in the body, thereby playing a neuroprotective effect on cerebral hemorrhage rats. In addition, the preparation can obviously improve the consciousness state of cerebral hemorrhage patients, alleviate the degree of neurological deficit, relieve the related TCM syndromes of the patients, simultaneously effectively improve the daily life ability of the patients, significantly improve the total effective rate of clinical treatment, and no obvious adverse reactions are observed in the treatment process, and the safety is good, thereby providing a safe and effective treatment scheme for the conservative treatment of cerebral hemorrhage.

The application belongs to the technical field of medicine, and particularly relates to a muscone derivative, a preparation method and application thereof. The muscone derivative cyclopentadecanedione monoxime has obvious advantages over muscone and other derivatives in improving the MCAO rat mNSS score, microcirculation blood flow, reducing the cerebral infarction rate, the cortical and hippocampal neuron necrosis rate, and the brain water content, and increasing the SOD and CAT contents of the rat brain tissue which are abnormally reduced due to ischemia, and is a potential effective drug for cerebral ischemia-reperfusion injury.

The invention provides a traditional Chinese medicine preparation for treating or improving cerebral hemorrhage and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of nacre mother of pearl, antelope horn powder, dragon's blood, motherwort fruit, selfheal, aspongopus, radix actinidiae chinensis, bamboo juice, pericarpium citri reticulatae, selaginella tamariscina, radix puerariae, zizania aquatica and folium eriobotryae. The traditional Chinese medicine composition can obviously improve neurological impairment of cerebral hemorrhage rats, reduce the water content of brain tissues to relieve encephaledema and reduce inflammatory response in vivo, thereby playing a role in protecting the nerves of the cerebral hemorrhage rats. Besides, the preparation can obviously improve the consciousness state of a cerebral hemorrhage patient, relieve the degree of neurological impairment, relieve related traditional Chinese medicine syndromes of the patient, effectively improve the daily living ability of the patient and obviously improve the total effective rate of clinical treatment, no obvious adverse reaction is observed in the treatment process, and the preparation is good in safety and free of toxic and side effects. And a safe and effective treatment scheme is provided for the conservative treatment of cerebral hemorrhage.

The application provides a construction method and application of a Toxoplasma gondii attenuated strain PruDelta pp2a-c and belongs to the technical field of biological medicine. The TgPP2A-C gene is knocked out to obtain a TgPP2A-C gene deletion Toxoplasma gondii attenuated strain. After the gene is deleted, a large number of starch granules are aggregated between the bodies of the Toxoplasma gondii, and the Toxoplasma gondii loses the ability to form cysts. The in-vitro proliferation speed and pathogenicity of the TgPP2A-C gene deletion Toxoplasma gondii attenuated strain are significantly reduced compared with those of a wild strain. After being infected with the TgPP2A-C gene deletion strain, a mouse does not get ill or die, and no cysts are detected in the brain tissue of the mouse, so the TgPP2A-C gene deletion strain has high safety to a host. After a mouse is immunized with the TgPP2A-C gene deletion Toxoplasma gondii attenuated strain, the antibody level of the mouse is significantly improved, and the mouse can provide significant immunoprotection efficacy against high-dose Toxoplasma gondii RH tachyzoite and Pru cyst re-infection, and can prevent re-infection of Toxoplasma gondii.

The invention provides an establishment method and application of a Zika virus infectious animal model, and belongs to the technical field of biology. According to the invention, ZIKV is inoculated to Toll-like receptor-deleted animals, such that the ZIKV challenging animal model is obtained. After the animal is inoculated with ZIKV, obvious ZIKV load can be detected in blood, liver, spleen, reproductive organ and brain tissue of the animal, moreover, the spleen is obviously swollen, the liver tissue has punctiform necrotic lesion, the splenosome is obviously reduced, and the mRNA level of inflammation related indexes Ccl5, Cxcl1, Isg15 and Isg56 is obviously up-regulated, which indicates that the ZIKV challenge model disclosed by the invention is successfully constructed; the method can be used in related researches such as ZIKV infection mechanism, vaccine research and development, anti-ZIKV drug research and development and the like.

An autophagy biomarker related to depression, a risk assessment model and its application. Through multi-dimensional screening of large sample data and machine learning algorithms, the present invention screens out a group of autophagy-related biomarkers for the auxiliary diagnosis of depression, including the following genes: GABARAPL2, RB1CC1, FOS, ULK1, and the differential expression thereof is confirmed in the cortical brain tissue of chronically stressed depression-like mice. The present invention also provides a risk assessment model for the auxiliary diagnosis of depression. A logistic regression model is constructed with the said biomarkers as features, the score formula and risk threshold for the risk assessment of depression are determined, and the prediction performance of the model is evaluated in various aspects. The said prediction model has good prediction accuracy and calibration, can efficiently and conveniently achieve the early diagnosis of depression, and improve the accuracy of depression treatment.

The present application belongs to the technical field of nutrient research, and particularly relates to a nutrient composition for promoting brain development and use thereof. The nutrient composition provided by the present application comprises two necessary components: i) lysophosphatidyl ethanolamine; and ii) docosahexaenoic acid; and the mass ratio of the lysophosphatidyl ethanolamine to the docosahexaenoic acid in the nutrient composition is 1:(10-2100). The combination of lysophosphatidyl ethanolamine and docosahexaenoic acid can effectively promote the overall growth and development of the body, especially the brain development, increase the expression levels of brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in brain tissue, and effectively assist the improvement of cognitive ability.

The invention relates to the technical field of biological medicine and polymer targeted delivery, and provides an oligodendrocyte-derived exosome and application thereof in preparation of a medicine for treating traumatic brain injury. Comprising the following steps: separating and culturing primary oligodendroglia cells from brain tissues; placing the maturely cultured oligodendroglia cells in a sugar-free and serum-free culture medium, performing oxygen-glucose deprivation treatment in an anoxic environment, then continuously culturing in a normal sugar-containing culture medium under a normal oxygen condition, and collecting cell culture supernate; and separating the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment from the supernate by adopting a gradient ultracentrifugation method to obtain the exosome of the oligodendroglia cells subjected to oxygen-glucose deprivation treatment. The exosome derived from the oligodendroglia is applied to preparation of the medicine for treating the traumatic brain injury and has the advantages of being high in targeting performance and good in penetrability, that is, the exosome is used as a natural carrier, the defect that a traditional traumatic brain injury medicine is difficult to penetrate through a blood brain barrier is perfectly overcome, and the exosome can efficiently enter brain tissue and be taken by microglia.

Among the various aspects of the present disclosure is the provision of a noninvasive and localized brain liquid biopsy using focused ultrasound. Briefly, therefore, the present disclosure is directed to methods and systems to identify brain lesion or tumor characteristics without the need for a solid brain biopsy.

The application discloses application of RVG-Exo-miR-3059-5 in treating cerebral stroke. The RVG-Exo-miR-3059-5 is prepared by using gene engineering technology to perform brain targeting modification on EPCs-Exo and load miR-3059-5p drugs. The experiment proves that the RVG-Exo-miR-3059-5 can effectively target brain tissues, can prevent or treat cerebral stroke, and can improve the prognosis of cerebral stroke patients.

The invention provides a gene composition for screening or diagnosing Parkinson's syndrome and application of the gene composition, and belongs to the technical field of biology. The invention provides a set of seven genes in brain tissue, a set of eight genes in cerebrospinal fluid, a set of ten genes in blood and a set of eight DNA methylation sites in blood, and at least one of the sets can be used as a marker for screening or diagnosing Parkinson's syndrome. Meanwhile, based on the genotype, expression level or methylation level data of the marker, a model for diagnosing the Parkinson's syndrome is constructed by combining a maximum logic intelligent classifier, and the subtype of the Parkinson's syndrome is determined. The method does not depend on a p value and multiple inspection correction, but establishes the model by searching the minimum and optimal gene combinations capable of perfectly distinguishing cases and contrasts, thereby fundamentally avoiding the problems of overfitting and insufficient statistical efficacy.